Part III · Mechanism
What goes wrong while the range is rising
None of this is a malfunction. Each change described below is a normal response, working as designed, in circumstances that no longer suit it. The difficulty is that several of these responses are self-reinforcing, which is why the defended range does not simply drift back down when conditions improve.
The short answer
In obesity, leptin levels are high, but less of the signal reaches the brain, so the higher weight is defended as though it were correct. At the same time, the switch between burning fat and burning carbohydrate becomes less responsive, adipose tissue becomes inflamed, and fat accumulates in the liver and muscle. The system has not switched off. Several of its components now respond differently, and together they reinforce the higher-weight state.
The leptin signal rises, and less of it reaches the brain
Leptin is the body's readout on stored energy. As fat mass increases, leptin rises, and higher leptin should mean less hunger.C-II-01 In obesity, leptin levels are high, often very high, and yet appetite is not suppressed to match. The signal is being sent loudly, yet it is not having its expected effect.C-III-16
The usual shorthand is that the brain tunes the signal out. Recent work suggests something more specific: that less leptin gets across the blood-brain barrier, so the brain is not ignoring the message so much as receiving a quieter version of it.C-III-16
The result is that the body defends the higher weight as though it were the correct one.
This is the step that converts an upward drift into a new setting rather than a temporary excursion. It also explains why the defense is asymmetric: the machinery that should object to further gain is the same machinery whose signal has been turned down.
Fuel switching becomes less responsive
In a healthy system, metabolism switches fuels according to what is available, burning fat between meals and after fasting and turning to carbohydrate when it arrives. That capacity is known as metabolic flexibility, and it is impaired in obesity and insulin resistance.C-III-14
Importantly, this is not a question of metabolism being "fast" or "slow." The change is in how readily the body moves from one fuel to the other.
Fat tissue begins to behave differently
Adipose tissue is not inert storage but an endocrine organ, and in obesity it becomes inflamed: immune cells infiltrate it, and it produces a more inflammatory signaling profile. The result is a state of chronic, low-grade inflammation, one that has been demonstrated in human adipose tissue rather than inferred from animal models.C-III-15
Whether inflammation drives obesity or follows from it remains contested, and nothing described here settles the question.
Fat accumulates where it does not belong
In obesity, fat can accumulate outside adipose tissue, in the liver and in muscle. This ectopic fat drives insulin resistance in both tissues, and it is the link between obesity, fatty liver disease, and metabolic syndrome.C-III-17
This is also where the assumption that weight and illness are the same thing breaks down. At the same body weight, people with less ectopic fat show preserved insulin sensitivity.C-III-17 Weight on its own is not a sufficient description of metabolic health; where the fat is stored matters as much as how much of it there is.
The gut barrier, where the story runs ahead of the evidence
There is a mechanism you will encounter constantly: the intestinal barrier becomes more permeable, bacterial products cross into the circulation, and the resulting inflammation drives metabolic disease. The account is compelling and mechanistically plausible.
Why any of this matters
Nothing described here has stopped working. Leptin is still being produced, and in larger amounts than ever. Adipose tissue is still signaling. The fuel switch still exists. The system is intact and doing what it is designed to do.C-I-02
What has changed is that its outputs now sustain the state that produced them. High fat mass produces high leptin; high leptin arrives at the brain attenuated; appetite stays up; fat mass stays high. The loop closes, and the defended range settles at its new level rather than returning to the old one.
In practical terms, advice to simply eat less asks a person to counteract this loop by hand, indefinitely, while the loop itself continues to run automatically.
References
- Lea AJ, et al. Applying an evolutionary mismatch framework to understand disease susceptibility. PLoS Biol. 2023. PMID 37695771
- Brassington L, et al. Integrating the Thrifty Genotype and Evolutionary Mismatch Hypotheses to understand variation in cardiometabolic disease risk. Evol Med Public Health. 2024. PMID 39484023
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes. 2010. PMC3673773
- Physiology, Obesity Neurohormonal Appetite and Satiety Control. StatPearls. NBK NBK555906
- Scherer T, et al. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol. 2021. PMID 34108679
- Dodd GT, Tiganis T. Insulin action in the brain: Roles in energy and glucose homeostasis. J Neuroendocrinol. 2017. PMID 28758251
- Vogt MC, Bruning JC. CNS insulin signaling in the control of energy homeostasis and glucose metabolism. Trends Endocrinol Metab. 2013. PMID 23265947
- Speakman JR, et al. Set points, settling points and some alternative models. Dis Model Mech. 2011. PMID 22065844
- Models of body weight and fatness regulation. Phil Trans R Soc B. 2023. PMC10475878
- Izquierdo AG, et al. Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later? Nutrients. 2019. PMID 31717265
- Liu J, et al. The Leptin Resistance. Adv Exp Med Biol. 2018. PMID 30390289
- Engin A. The Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective. Adv Exp Med Biol. 2024. PMID 39287862
- Galgani JE, et al. Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab. 2008. PMID 18765680
- Hansen M, et al. Are Individuals With Type 2 Diabetes Metabolically Inflexible? A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2025. PMID 40318136
- Zatterale F, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020. PMID 32063863
- Esser N, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014. PMID 24798950
- Cancello R, Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG. 2006. PMID 16903845
- Janssen JAMJL. The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome. Int J Mol Sci. 2024. PMID 39769002
- Byrne CD. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc. 2013. PMID 23668723
- Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease. Mol Cell Endocrinol. 2015. PMID 25724480
- Bluher M. Metabolically Healthy Obesity. Endocr Rev. 2020. PMID 32128581
- Neves AL, et al. Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J Mol Endocrinol. 2013. PMID 23943858
- Teixeira TFS, et al. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res. 2012. PMID 23084636
- Koutoukidis DA, et al. The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis. Gut Microbes. 2022. PMID 35040746
- Ferolla SM, et al. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients. 2016. PMID 27367724